Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000426068

Medchemexpress LLC Cibinetide (ARA290) | 1208243-50-8 | >99.9% | 1257.31 | 10 MG
SDP

Catalog No. 5000426068
Encompass_Preferred

Cibinetide (ARA290) is an erythropoietin (EPO) derivative that acts as a specific agonist of the erythropoietin/CD131 heteroreceptor. It is investigated for neurological disorders and has shown promise in enhancing endothelial colony-forming cell functions and attenuating EAE severity in rats. This EPO-analog peptide is notable for its potential neurotrophic and antidepressant effects without hematopoietic side-effects.

  • Acts as a specific agonist of the erythropoietin/CD131 heteroreceptor
  • Enhances proliferation, migration, and resistance to H2O2-induced apoptosis of endothelial colony-forming cells
  • May have neurotrophic and antidepressant effects
  • Prevents progressive worsening of glucose control in rats
  • Delays onset, decreases neurologic severity, and shortens duration of EAE in a dose-dependent way

Catalog No. 50-004-26068 Supplier Medchemexpress LLC Supplier No. HYP016810MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Cibinetide (ARA290) is an erythropoietin (EPO) derivative that acts as a specific agonist of the erythropoietin/CD131 heteroreceptor. It is investigated for neurological disorders and has shown promise in enhancing endothelial colony-forming cell functions and attenuating EAE severity in rats. This EPO-analog peptide is notable for its potential neurotrophic and antidepressant effects without hematopoietic side-effects.

  • Acts as a specific agonist of the erythropoietin/CD131 heteroreceptor
  • Enhances proliferation, migration, and resistance to H2O2-induced apoptosis of endothelial colony-forming cells
  • May have neurotrophic and antidepressant effects
  • Prevents progressive worsening of glucose control in rats
  • Delays onset, decreases neurologic severity, and shortens duration of EAE in a dose-dependent way

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.